Comparison of 1-day versus 3-day intravenous terlipressin in cirrhosis patients with variceal bleeding: A pilot randomised controlled trial.

Manas VaishnavSagnik BiswasAbhishek ShenoyPiyush PathakAbhinav AnandShekhar SwaroopArnav AggrawalVineet AhujaAnshuman ElhenceSoumya JagannathDeepak GunjanSaurabh KediaAshwani Kumar MishraShivanand GamanagattiBaibaswata NayakPramod Garg. Shalimar

Published in: Alimentary pharmacology & therapeutics (2024)

Our results suggest that 1 day of terlipressin therapy is associated with similar 5-day and 42-day rebleeding rates, 42-day mortality and an overall superior safety profile compared with 3-day of terlipressin therapy. These findings require to be validated in double-blinded, larger, multiethnic and multicentre studies across the various stages of cirrhosis (CTRI/2019/10/021771).

Keyphrases

study protocol
clinical trial
high dose
stem cells
type diabetes
cross sectional
replacement therapy
clinical evaluation